KLK7 Inhibitors

KLK7 inhibitors as a chemical class consist of molecules that can interact with the active site or modulate the function of kallikrein-related peptidase 7. Inhibitors typically target the serine protease activity of KLK7, either directly by binding to its active site or indirectly through modulating associated proteolytic pathways. Molecules like AEBSF, leupeptin, and aprotinin are designed to interact with the active sites of serine proteases, preventing them from engaging with their specific substrates. Such interactions lead to a decrease in protease activity, which in the context of KLK7, translates to reduced proteolysis. The inhibition of KLK7 can also be achieved indirectly by compounds that modulate related pathways. Metalloprotease inhibitors like phosphoramidon, or broad-spectrum serine protease inhibitors such as gabexate mesilate and camostat mesilate, do not inhibit KLK7 directly but may affect its activity through systemic alterations in protease networks. Matrix metalloproteinase inhibitors like marimastat and ilomastat are not selective for KLK7 but could indirectly impact its function through changes in the extracellular matrix, which can influence the environment where KLK7 is active. Chymostatin, targeting chymotrypsin-like proteases, also has the potential to affect the activity of related proteases, thereby influencing the biological processes KLK7 is involved in.